CHARCOT-MARIE-TOOTH SUBTYPE BIOMARKERS AND OUTCOME MEASURES IN SUBJECTS WITH CMT1B, CMT2A, CMT2F AND CMT1X

被引：0
|
作者：
Dragon, Amanda [1 ]
Reilly, Mary [2 ]
Svaren, John [3 ]
Scherer, Steven [4 ]
Pareyson, Davide [5 ]
Herrmann, David [6 ]
Shy, Michael E. [1 ]
机构：
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] UCL Queen Sq Inst Neurol, London, England
[3] Univ Wisconsin Madison, Madison, WI USA
[4] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy
[6] Univ Rochester, Dept Neurol, Rochester, MN USA
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2024年 / 29卷
关键词：
CMT; Charcot-Marie-Tooth; neuropathy;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P 044
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [41] Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)
    Michael W Sereda
    Gerd Meyer zu Hörste
    Ueli Suter
    Naureen Uzma
    Klaus-Armin Nave
    Nature Medicine, 2003, 9 : 1533 - 1537
  • [42] Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)
    Sereda, MW
    Hörste, GMZ
    Suter, U
    Uzma, N
    Nave, KA
    NATURE MEDICINE, 2003, 9 (12) : 1533 - 1537
  • [43] Pathophysiological mechanisms of lamin A/C associated Charcot-Marie-Tooth disease (CMT2B1/ARCMT2)
    Poitelon, Y.
    Hamadouche, T.
    De Sandre-Giovannoli, A.
    Kozlov, S.
    Serradj, N.
    Tazir, M.
    Chaouch, M.
    Grid, D.
    Stewart, C.
    Jamon, M.
    Delague, V.
    Levy, N.
    NEUROMUSCULAR DISORDERS, 2006, 16 (9-10) : 675 - 675
  • [44] A NOVEL MUTATION IN VCP CAUSES CHARCOT-MARIE-TOOTH TYPE 2 (CMT2) DISEASE
    Gonzalez, M. A.
    Feely, S. M. E.
    Speziani, F.
    Bacon, C. C.
    Blanton, S.
    Lee, Y.
    Chou, T-F
    Weihl, C. C.
    Zuechner, S.
    Shy, M. E.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2015, 20 (02) : 151 - 151
  • [45] Charcot-Marie-Tooth Neuropathy (CMT) Type 2A2 in Children: A Retrospective Case Series
    Beeravolu, Lakshmi R.
    Iannaccone, Susan T.
    Sparagana, Steven P.
    NEUROLOGY, 2009, 72 (11) : A295 - A295
  • [46] LOCALIZATION OF X-LINKED DOMINANT CHARCOT-MARIE-TOOTH DISEASE (CMT 2) TO XQ13
    BECKETT, J
    HOLDEN, JJA
    SIMPSON, NE
    WHITE, BN
    MACLEOD, PM
    JOURNAL OF NEUROGENETICS, 1986, 3 (04) : 225 - 231
  • [47] INVESTIGATION OF SENSORS TO IDENTIFY GAIT BIOMARKERS IN INDIVIDUALS WITH CHARCOT-MARIE-TOOTH DISEASE TYPE 1A (CMT1A)
    Baker, Lindsay
    Dinesh, Karthik
    Sowden, Janet
    Behrens-Spraggins, Steffen
    Charles, Julie
    Wood, Elizabeth
    Sharma, Gaurav
    Herrmann, David
    Eichinger, Katy
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2022, 27 : S12 - S13
  • [48] Uneventful administration of cisplatin to a man with X-linked Charcot-Marie-Tooth disease (CMT)
    Cowie, F
    Barrett, A
    ANNALS OF ONCOLOGY, 2001, 12 (03) : 422 - 422
  • [49] Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
    Pareyson, Davide
    Reilly, Mary M.
    Schenone, Angelo
    Fabrizi, Gian Maria
    Cavallaro, Tiziana
    Santoro, Lucia
    Vita, Giuseppe
    Quattrone, Aldo
    Padua, Luca
    Gemignani, Franco
    Visioli, Francesco
    Laura, Matilde
    Radice, Davide
    Calabrese, Daniela
    Hughes, Richard A. C.
    Solari, Alessandro
    LANCET NEUROLOGY, 2011, 10 (04): : 320 - 328
  • [50] Efficacy and safety of PXT3003 in patients with Charcot-Marie-Tooth type 1A (CMT1A): results of PLEO-CMT an International Pivotal Phase 3 trial. For the PLEO CMT Investigators
    Young, P.
    Attarian, S.
    Youcef, B.
    Rinaudo, P.
    Fitoussi, S.
    Bertrand, V.
    Hajj, R.
    Nabirotchkin, S.
    Cohen, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 74 - 74
12345